In vivo 1H MRS of WSU-DLCL2 human non-Hodgkin's lymphoma xenografts: Response to rituximab and rituximab plus CHOP

NMR in Biomedicine

Volumn 22, Issue 3, 2009, Pages 259-265

  Lee, Seung Cheol ^a   Delikatny, Edward J ^a   Poptani, Harish ^a   Pickup, Stephen ^a   Glickson, Jerry D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Choline; Lactate; MRS; Non Hodgkin's lymphoma; RCHOP; Rituximab; SelMQC; STEAM

Indexed keywords

CHOLINE; LACTATE; MRS; NON-HODGKIN'S LYMPHOMA; RCHOP; RITUXIMAB; SELMQC;

BIOLOGICAL MATERIALS;

TUMORS;

CHOLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; KI 67 ANTIGEN; LACTIC ACID; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HETERONUCLEAR MULTIPLE QUANTUM COHERENCE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOASSAY; IN VIVO STUDY; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCID MOUSE; STIMULATED ECHO ACQUISITION MODE SEQUENCE; TUMOR MODEL; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; DRUG EFFECT; DRUG SCREENING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; TIME; TUMOR CELL LINE;

MUS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LYMPHOMA, NON-HODGKIN; MAGNETIC RESONANCE IMAGING; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 64949123236     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1316     Document Type: Article

References (42)

1. American Cancer Society. Cancer Facts and Figures, 2006; American Cancer Society: Atlanta, 2006.
2. Mauch PM, Armitage JO, Harris NL, Dalla-Favera R, Coiffier B. Non-Hodgkin's Lymphomas, 3rd edn. Lippincott Williams & Wilkins: Philadelphia, 2003.
3. Campbell P, Marcus R. Monoclonal antibody therapy for lymphoma. Blood Rev 2003; 17: 143-152.
4. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003; 63: 803-843.
5. Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998; 10: 548-551.
6. Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 2005; 54: 11-29.
7. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445.
8. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
9. Bhujwalla ZM, Glickson JD. Detection of tumor response to radiation therapy by in vivo proton MR spectroscopy. Int J Radiat Oncol Biol Phys 1996; 36: 635-639.
10. 1H magnetic resonance spectroscopy. Neoplasia 2006; 8: 560-567.
11. 1H spectroscopic imaging. Clin Cancer Res 2003; 9: 4529-4536.
12. Jagannathan NR, Kumar M, Seenu V, Coshic O, Dwivedi SN, Julka PK, Srivastava A, Rath GK. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 2001; 84: 1016-1022.
13. Bhujwalla ZM, Shungu DC, Glickson JD. Effects of blood flow modifiers on tumor metabolism observed in vivo by proton magnetic resonance spectroscopic imaging. Magn Reson Med 1996; 36: 204-211.
14. Poptani H, Bansal N, Graham RA, Mancuso A, Nelson DS, Glickson JD. Detecting early response to cyclophosphamide treatment of RIF-1 tumors using selective multiple quantum spectroscopy (SelMQC) and dynamic contrast enhanced imaging. NMR Biomed 2003; 16: 102-111.
15. 1H nuclear magnetic resonance spectroscopy: effect of 5-fluorouracil on lactate levels in radiation-induced fibrosarcoma 1 tumors. Cancer Res 1998; 58: 1063-1067.
16. Arias-Mendoza F, Smith MR, Brown TR. Predicting treatment response in non-Hodgkin's lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine. Acad Radiol 2004; 11: 368-376.
17. 31P MR spectral patterns and reproducibility in cancer patients studied in a multi-institutional trial. NMR Biomed 2006; 19: 504-512.
18. Gadian DG. NMR and its Applications to Living Systems. Oxford University Press: Oxford, 1996.
19. Lee S-C, Huang MQ, Nelson DS, Pickup S, Wehrli S, Adegbola O, Poptani H, Delikatny EJ, Glickson JD. In vivo MRS markers of response to CHOP chemotherapy in a human diffuse large B-cell lymphoma xenograft. NMR Biomed 2008; 21: 723-733.
20. Rodrigues LM, Stubbs M, Robinson SP, Newell B, Mansi J, Griffiths JR. The C-neu mammary carcinoma in Oncomice; characterization and monitoring response to treatment with herceptin by magnetic resonance methods. Magn Reson Mater Phys 2004; 17: 260-270.
21. Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin Cancer Res 2000; 6: 4950-4956.
22. Al-Katib AM, Smith MR, Kamanda WS, Pettit GR, Hamdan M, Mohamed AN, Chelladurai B, Mohammad RM. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res 1998; 4: 1305-1314.
23. Hornak JP, Szumowski J, Bryant RG. Elementary single turn solenoids used as the transmitter and receiver in magnetic resonator imaging. Magn Reson Imaging 1987; 5: 233-237.
24. He Q, Shungu DC, van Zijl PC, Bhujwalla ZM, Glickson JD. Single-scan in vivo lactate editing with complete lipid and water suppression by selective multiple-quantum-coherence transfer (Sel-MQC) with application to tumors. J Magn Reson B 1995; 106: 203-211.
25. Frahm JMK, Hanicke W. Localized proton spectroscopy using stimulated echoes. J Magn Reson 1987; 72: 502-508.
26. Ordidge RJ, Connelly A, Lohman JAB. Image-selected in vivo spectroscopy (ISIS). A. new technique for spatially selective NMR spectroscopy. J Magn Reson 1986; 66: 283-294.
27. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed 1992; 5: 303-324.
28. Ackerstaff E, Glunde K, Bhujwalla ZM. Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem 2003; 90: 525-533.
29. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999; 59: 80-84.
30. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2001; 61: 3599-3603.
31. Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S, Podo F. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res 2005; 65: 9369-9376.
32. Shimizu H, Kumabe T, Shirane R, Yoshimoto T. Correlation between choline level measured by proton MR spectroscopy and Ki-67 labeling index in gliomas. AJNR Am J Neuroradiol 2000; 21: 659-665.
33. Herminghaus S, Pilatus U, Moller-Hartmann W, Raab P, Lanfermann H, Schlote W, Zanella FE. Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors. NMR Biomed 2002; 15: 385-392.
34. 1H-magnetic resonance spectroscopy: correlation with histopathology and immunohistochemistry. Neuroradiology 2006; 48: 312-318.
35. 1H MRS choline: correlation with in vitro chemistry/histology. Life Sci 1996; 58: 1929-1935.
36. McKnight TR, Lamborn KR, Love TD, Berger MS, Chang S, Dillon WP, Bollen A, Nelson SJ. Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomas. J Neurosurg 2007; 106: 660-666.
37. Jordan BF, Black K, Robey IF, Runquist M, Powis G, Gillies RJ. Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo. NMR Biomed 2005; 18: 430-439.
38. Al-Saffar NM, Troy H, Ramirez de Molina A, Jackson LE, Madhu B, Griffiths JR, Leach MO, Workman P, Lacal JC, Judson IR, Chung YL. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res 2006; 66: 427-434.
39. Neeman M, Degani H. Metabolic studies of estrogen- and tamoxifentreated human breast cancer cells by nuclear magnetic resonance spectroscopy. Cancer Res. 1989; 49: 589-594.
40. 31P NMR studies of RIF-1 fibrosarcoma cells perfused in vitro. NMR Biomed. 1996; 9: 173-178.
41. Bui T, Thompson CB. Cancer's sweet tooth. Cancer Cell 2006; 9: 419-420.
42. Pickup S, Lee S-C, Mancuso A, Glickson JD. Lactate imaging with Hadamard-encoded slice-selective multiple quantum coherence chemical shift imaging. Magn Reson Med 2008; 60: 299-305.